Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2019 1
2020 2
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H, Kawata Y, Wright P, De Seze J. Yamamura T, et al. Among authors: kawata y. N Engl J Med. 2019 Nov 28;381(22):2114-2124. doi: 10.1056/NEJMoa1901747. N Engl J Med. 2019. PMID: 31774956 Clinical Trial.
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y, Kawata Y, Wright P, Gianella-Borradori A, Garren H, Weinshenker BG. Traboulsee A, et al. Among authors: kawata y. Lancet Neurol. 2020 May;19(5):402-412. doi: 10.1016/S1474-4422(20)30078-8. Lancet Neurol. 2020. PMID: 32333898 Free PMC article. Clinical Trial.
Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data.
Kuwana M, Tamura N, Yasuda S, Fujio K, Shoji A, Yamaguchi H, Iwasaki K, Makishima M, Kawata Y, Yamashita K, Igarashi A. Kuwana M, et al. Among authors: kawata y. Mod Rheumatol. 2023 Mar 2;33(2):302-311. doi: 10.1093/mr/roac038. Mod Rheumatol. 2023. PMID: 35445720
Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study.
Kinugasa E, Igawa K, Shimada H, Kondo M, Funakoshi S, Imada N, Itami N, Fukazawa N, Takubo R, Kawata Y, Murota H. Kinugasa E, et al. Among authors: kawata y. Clin Exp Nephrol. 2021 Aug;25(8):875-884. doi: 10.1007/s10157-021-02047-2. Epub 2021 Mar 22. Clin Exp Nephrol. 2021. PMID: 33754202 Free PMC article. Clinical Trial.